Fusion Antibodies plc

Default features description for sign up page.

Company Presentations

Updates

Regulatory News

Board Profiles

Company Profile

Home

Fusion Deep Dive

Shareholder Information

Share Price

New investors

Advisers

Registrar & FAQs

Corporate Governance

Raleway

In this episode, Chief Scientific Officer Richard Buick provides an in-depth look at Fusion’s DR5 antibody programme, see the RNS announcement of the approval of grant funding here. This 18-month grant-funded initiative is focused on developing a clinic-ready therapeutic antibody targeting death receptor 5 (DR5), a well-validated oncology target.

Richard breaks down why DR5 has long held promise in cancer treatment and explains why previous antibody candidates have struggled to progress beyond early-stage trials. He outlines the complexities of designing antibodies against this target and highlights what makes Fusion’s candidate structurally unique and potentially more effective.

With grant funding secured and Fusion’s humanisation expertise supporting preclinical development, the project is progressing toward key commercial milestones. Richard also discusses the opportunity to out-license the candidate to pharmaceutical partners and what success could look like for Fusion and its shareholders.

Watch the full breakdown of the DR5 programme and submit your questions below.